The purpose of this study is to assess the bioavailability of Divalproex Sodium DR Tablets 500 mg versus Depakote DR 500 mg tablets with a washout period of 10 days in healthy subjects.

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study of Divalproex sodium DR 500 mg tablets of Dr.Reddy's Laboratories Limited, Generics, India comparing with that of Depakote® DR (containing Divalproex sodium) 500 mg tablets of Abbott Laboratories PR Ltd., Barceloneta, PR, in healthy, adult, human subjects under fasting conditions.

Inclusion Criteria:

Subjects must fulfill all of the following criteria to be considered for inclusion into this study:

• Subjects who will provide written informed consent.
• Subjects must be healthy, adult, human beings within 18-45 years of age (both inclusive)weighing at least 50 kg.
• Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as weight in Kg/height in m2
• Subjects must be of normal health as determined by medical history and physical examination performed within 21 days prior to the commencement of the study.
• Subjects whose screening laboratory values are within normal limits or considered by the physician/investigator to be of no clinical significance.
• Availability of the subject for the entire study period and willingness to adhere to the protocol requirements as evidenced by written informed consent.

Exclusion Criteria:

The subjects will be excluded based on the following criteria during screening and during the study

• Subjects incapable of understanding the informed consent.

• Subjects who have:

  • Systolic blood pressure less than 90 mm of Hg and more than 140 mm of Hg
  • Diastolic blood pressure less than 60 mm of Hg and more than 94 mm of Hg. Minor deviations (2-4 mm of Hg) at check-in may be acceptable at the discretion of the physician/investigator.
  • Pulse rate below 50/min and above 100/min.

• History of hypersensitivity or idiosyncratic reaction to Divalproex sodium or any other related drugs.

• Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function.

• Consumption of grapefruit for the past ten days prior to the dosing day until the completion of the study.

• Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking from 48 hours before dosing and during sampling period

• Subjects who have taken over the counter or prescribed medications and enzyme modifying or any systemic medication for during the last 7 and 30 days respectively before dosing.

• Subjects who have participated in any other clinical investigation using experimental drug/donated blood in past 90 days before the date of start of study.

• Subjects with clinically significant abnormalities (such as Laboratory Findings, ECG, X-Ray,Drugs of abuse, Alcohol etc.,) and/or with significant diseases (such as HIV, HCV, Syphilis,Hepatitis B etc.,).

• Female subjects who are pregnant or who are able (women with child bearing potential) to become pregnant during the study.